10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CSRNP2 Antibody (C-term) Blocking peptide

Synthetic peptide
Catalog # BP13477b

Specification

CSRNP2 Antibody (C-term) Blocking peptide - Product Information

Primary Accession Q9H175

CSRNP2 Antibody (C-term) Blocking peptide - Additional Information

Gene ID 81566

Other Names
Cysteine/serine-rich nuclear protein 2, CSRNP-2, Protein FAM130A1, TGF-beta-induced apoptosis protein 12, TAIP-12, CSRNP2, C12orf22, FAM130A1, TAIP12

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP13477b was selected from the C-term region of CSRNP2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CSRNP2 Antibody (C-term) Blocking peptide - Protein Information

Name CSRNP2

Synonyms C12orf22, FAM130A1, TAIP12

Function
Binds to the consensus sequence 5'-AGAGTG-3' and has transcriptional activator activity (By similarity). May play a role in apoptosis.

Cellular Location
Nucleus.

CSRNP2 Antibody (C-term) Blocking peptide - Protocols

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

CSRNP2 Antibody (C-term) Blocking peptide - Images

CSRNP2 Antibody (C-term) Blocking peptide - Background

CSRNP2 binds to the consensus sequence 5'-AGAGTG-3' and has transcriptional activator activity (By similarity). May play a role in apoptosis.

CSRNP2 Antibody (C-term) Blocking peptide - References

Gingras, S., et al. PLoS ONE 2 (8), E808 (2007) :Colland, F., et al. Genome Res. 14(7):1324-1332(2004)